CA Patent

CA3164445A1 — Intranasal pharmaceutical compositions of cgrp inhibitors

Assigned to Pfizer Ireland Pharmaceuticals · Expires 2021-06-24 · 5y expired

What this patent protects

Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intr…

USPTO Abstract

Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intranasally administering to the subject a composition including a therapeutically active component including a CGRP inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
CA3164445A1
Jurisdiction
CA
Classification
—
Expires
2021-06-24
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Ireland Pharmaceuticals
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.